Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Lopalco

Showing results (121-130 of 221) with videos related to

Pageof 23
Sort By:
Journal of Clinical Medicine|January 21, 2023
From Bench to Bedside in Rheumatoid Arthritis from the "2022 GISEA International Symposium"Antonio Vitale, Stefano Alivernini, Roberto Caporali, et al.
Clinical Rheumatology|November 18, 2016
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational studyClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
Clinical Rheumatology|June 24, 2014
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in ItalyLuca Cantarini, Antonio Vitale, Orso Maria Lucherini, et al.
Clinical Rheumatology|April 4, 2018
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitisClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
The British Journal of Ophthalmology|August 28, 2017
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up studyClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Journal of Autoimmunity|April 24, 2026
PPAR-γ dysregulation links NF-κB activation and Nrf2-driven antioxidant responses in axial spondyloarthritis: A pilot studyGiuseppe Lopalco, Giuseppe Carota, Nicolò Musso, et al.
Ocular Immunology and Inflammation|November 4, 2017
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related UveitisClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Mediators of Inflammation|March 19, 2019
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective StudyAlice Bitossi, Alessandra Bettiol, Elena Silvestri, et al.
Archives of Rheumatology|August 28, 2020
Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) RegistryMarco Sebastiani, Andreina Manfredi, Florenzo Iannone, et al.
Clinical and Experimental Rheumatology|March 2, 2023
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre studyEdoardo Conticini, Miriana d'Alessandro, Silvia Grazzini, et al.
Pageof 23

Showing results (121-130 of 221) with videos related to

Sort By:
Pageof 23
Journal of Clinical Medicine|January 21, 2023
From Bench to Bedside in Rheumatoid Arthritis from the "2022 GISEA International Symposium"Antonio Vitale, Stefano Alivernini, Roberto Caporali, et al.
Clinical Rheumatology|November 18, 2016
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational studyClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
Clinical Rheumatology|June 24, 2014
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in ItalyLuca Cantarini, Antonio Vitale, Orso Maria Lucherini, et al.
Clinical Rheumatology|April 4, 2018
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitisClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
The British Journal of Ophthalmology|August 28, 2017
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up studyClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Journal of Autoimmunity|April 24, 2026
PPAR-γ dysregulation links NF-κB activation and Nrf2-driven antioxidant responses in axial spondyloarthritis: A pilot studyGiuseppe Lopalco, Giuseppe Carota, Nicolò Musso, et al.
Ocular Immunology and Inflammation|November 4, 2017
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related UveitisClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Mediators of Inflammation|March 19, 2019
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective StudyAlice Bitossi, Alessandra Bettiol, Elena Silvestri, et al.
Archives of Rheumatology|August 28, 2020
Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) RegistryMarco Sebastiani, Andreina Manfredi, Florenzo Iannone, et al.
Clinical and Experimental Rheumatology|March 2, 2023
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre studyEdoardo Conticini, Miriana d'Alessandro, Silvia Grazzini, et al.
Pageof 23